Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature review

Detalhes bibliográficos
Autor(a) principal: Maciel , Fernanda Duarte
Data de Publicação: 2023
Outros Autores: Fonseca, Maria Eduarda, Franco, Jéssyka Viana Valadares, Azeredo , João Paulo Silva, Lima, Allan Michael de, Almeida , Fernanda Viana de, Silva , Fernanda Paim Braga da, Aguiar , Késia Castro de, Lobo, Gustavo Soares, Leal, João Paulo de Jesus Soares
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/40259
Resumo: Attention Deficit Hyperactivity Disorder (ADHD) is a neurological disorder that is associated with poor brain performance. Individuals with ADHD have dyslexia, a certain impulsiveness and difficulty concentrating, resulting in poor school development. Taking into account, about 2.5 million new cases are declared per year in Brazil, whether due to real necessity or mere mediocrity of the diagnosis. Lisdexamfetamine methylphenidate is the main representative of a new class of long-acting agents for the treatment of ADHD, in current scenarios it has been the drug traditionally used as first choice for the treatment of children and adolescents with ADHD. Therefore, the general objective of this study was to analyze the effects that lisdexamfetamine dimesylate has for individuals with ADHD. In the methodology, a literature review was carried out, including studies in Portuguese and published between 2017 and 2022. Data collection took place in PubMed, LILACS, Scielo and Google Scholar databases. In the results, the safety and efficacy of lisdexamfetamine dimesylate for patients with ADHD proved to be effective and positive. In the studies found, it was understood that this drug has as its mechanism of action the blockade of the reuptake of the neurotransmitter dopamine and the stimulus to its production and noradrenaline. This action is what makes the stimulant of this medicine effective.
id UNIFEI_ae11f74ac5b6efaabe1e9489ca620789
oai_identifier_str oai:ojs.pkp.sfu.ca:article/40259
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature reviewSeguridad y eficacia del dimesilato de lisdexanfetamina en el trastorno por déficit de atención con hiperactividad: una revisión de la literaturaSegurança e eficácia do dimesilato de lisdexanfetamina em transtorno de déficit de atenção e hiperatividade: uma revisão literáriaDimesilato de lisdexanfetaminaDesorden de déficit de atenciónHiperactividadEficiencia.Dimesilato de LisdexanfetaminaTranstorno de déficit de atençãoHiperatividadeEficácia.Lisdexamfetamine dimesylateAttention deficit disorderHyperactivityEfficiency.Attention Deficit Hyperactivity Disorder (ADHD) is a neurological disorder that is associated with poor brain performance. Individuals with ADHD have dyslexia, a certain impulsiveness and difficulty concentrating, resulting in poor school development. Taking into account, about 2.5 million new cases are declared per year in Brazil, whether due to real necessity or mere mediocrity of the diagnosis. Lisdexamfetamine methylphenidate is the main representative of a new class of long-acting agents for the treatment of ADHD, in current scenarios it has been the drug traditionally used as first choice for the treatment of children and adolescents with ADHD. Therefore, the general objective of this study was to analyze the effects that lisdexamfetamine dimesylate has for individuals with ADHD. In the methodology, a literature review was carried out, including studies in Portuguese and published between 2017 and 2022. Data collection took place in PubMed, LILACS, Scielo and Google Scholar databases. In the results, the safety and efficacy of lisdexamfetamine dimesylate for patients with ADHD proved to be effective and positive. In the studies found, it was understood that this drug has as its mechanism of action the blockade of the reuptake of the neurotransmitter dopamine and the stimulus to its production and noradrenaline. This action is what makes the stimulant of this medicine effective.El Trastorno por Déficit de Atención con Hiperactividad (TDAH) es un trastorno neurológico que se asocia con un rendimiento cerebral deficiente. Las personas con TDAH presentan dislexia, cierta impulsividad y dificultad para concentrarse, lo que se traduce en un pobre desarrollo escolar. Teniendo en cuenta que cerca de 2,5 millones de nuevos casos son declarados por año en Brasil, ya sea por necesidad real o por mera mediocridad del diagnóstico. El metilfenidato de lisdexanfetamina es el principal representante de una nueva clase de agentes de acción prolongada para el tratamiento del TDAH, en los escenarios actuales ha sido el fármaco tradicionalmente utilizado como primera elección para el tratamiento de niños y adolescentes con TDAH. Por tanto, el objetivo general de este estudio fue analizar los efectos que tiene el dimesilato de lisdexanfetamina en personas con TDAH. En la metodología, se realizó una revisión de la literatura, incluyendo estudios en portugués y publicados entre 2017 y 2022. La recolección de datos se realizó en las bases de datos PubMed, LILACS, Scielo y Google Scholar. En los resultados, la seguridad y eficacia del dimesilato de lisdexanfetamina para pacientes con TDAH demostró ser efectiva y positiva. En los estudios encontrados se entendió que este fármaco tiene como mecanismo de acción el bloqueo de la recaptación del neurotransmisor dopamina y el estímulo a su producción y noradrenalina. Esta acción es la que hace que el estimulante de este medicamento sea efectivo.Transtorno do Déficit de Atenção com Hiperatividade (TDAH) é um distúrbio neurológico que está afiliado a um diferente desempenho do cérebro. Indivíduos com TDAH apresentam dislexia, uma certa impulsividade e dificuldade de concentração, acarretando num baixo desenvolvimento escolar. Levando em consideração, cerca de 2,5 milhões de novos casos são declarados por ano no Brasil, sendo eles por necessidade real ou mera mediocrização do diagnóstico. O Metilfenidato de Lisdexanfetamina é o principal representante de uma nova classe de agentes de ação prolongada para o tratamento de TDAH, nos cenários atuais tem sido a droga tradicionalmente utilizada em primeira escolha, para o tratamento de crianças e adolescentes com TDAH. Diante disso, o objetivo geral deste estudo foi analisar os efeitos que o dimesilato de lisdexanfetamina possui para os indivíduos portadores de TDAH. Na metodologia, foi realizada uma revisão da literatura onde foram incluídos estudos em língua portuguesa e publicados entre 2017 a 2022. A coleta de dados se deu nas bases de dados PubMed, LILACS, Scielo e Google Acadêmico. Nos resultados, a segurança e eficácia do dimesilato de lisdexanfetamina para pacientes com TDAH se mostrou eficaz e positiva. Nos estudos encontrados, entendeu-se que esse medicamento tem como mecanismo de ação o bloqueio da recaptação do neurotransmissor dopamina e o estímulo à produção dela e de noradrenalina. Essa ação é que torna efetivo o estimulante deste medicamento.Research, Society and Development2023-02-13info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/4025910.33448/rsd-v12i2.40259Research, Society and Development; Vol. 12 No. 2; e28412240259Research, Society and Development; Vol. 12 Núm. 2; e28412240259Research, Society and Development; v. 12 n. 2; e284122402592525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/40259/32963Copyright (c) 2023 Fernanda Duarte Maciel ; Maria Eduarda Fonseca; Jéssyka Viana Valadares Franco; João Paulo Silva Azeredo ; Allan Michael de Lima; Fernanda Viana de Almeida ; Fernanda Paim Braga da Silva ; Késia Castro de Aguiar ; Gustavo Soares Lobo; João Paulo de Jesus Soares Lealhttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMaciel , Fernanda Duarte Fonseca, Maria EduardaFranco, Jéssyka Viana Valadares Azeredo , João Paulo Silva Lima, Allan Michael de Almeida , Fernanda Viana de Silva , Fernanda Paim Braga da Aguiar , Késia Castro de Lobo, Gustavo Soares Leal, João Paulo de Jesus Soares 2023-02-14T20:07:52Zoai:ojs.pkp.sfu.ca:article/40259Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2023-02-14T20:07:52Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature review
Seguridad y eficacia del dimesilato de lisdexanfetamina en el trastorno por déficit de atención con hiperactividad: una revisión de la literatura
Segurança e eficácia do dimesilato de lisdexanfetamina em transtorno de déficit de atenção e hiperatividade: uma revisão literária
title Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature review
spellingShingle Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature review
Maciel , Fernanda Duarte
Dimesilato de lisdexanfetamina
Desorden de déficit de atención
Hiperactividad
Eficiencia.
Dimesilato de Lisdexanfetamina
Transtorno de déficit de atenção
Hiperatividade
Eficácia.
Lisdexamfetamine dimesylate
Attention deficit disorder
Hyperactivity
Efficiency.
title_short Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature review
title_full Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature review
title_fullStr Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature review
title_full_unstemmed Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature review
title_sort Safety and efficacy of lisdexamfetamine dimesylate in attention déficit hyperactivity disorder: a literature review
author Maciel , Fernanda Duarte
author_facet Maciel , Fernanda Duarte
Fonseca, Maria Eduarda
Franco, Jéssyka Viana Valadares
Azeredo , João Paulo Silva
Lima, Allan Michael de
Almeida , Fernanda Viana de
Silva , Fernanda Paim Braga da
Aguiar , Késia Castro de
Lobo, Gustavo Soares
Leal, João Paulo de Jesus Soares
author_role author
author2 Fonseca, Maria Eduarda
Franco, Jéssyka Viana Valadares
Azeredo , João Paulo Silva
Lima, Allan Michael de
Almeida , Fernanda Viana de
Silva , Fernanda Paim Braga da
Aguiar , Késia Castro de
Lobo, Gustavo Soares
Leal, João Paulo de Jesus Soares
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Maciel , Fernanda Duarte
Fonseca, Maria Eduarda
Franco, Jéssyka Viana Valadares
Azeredo , João Paulo Silva
Lima, Allan Michael de
Almeida , Fernanda Viana de
Silva , Fernanda Paim Braga da
Aguiar , Késia Castro de
Lobo, Gustavo Soares
Leal, João Paulo de Jesus Soares
dc.subject.por.fl_str_mv Dimesilato de lisdexanfetamina
Desorden de déficit de atención
Hiperactividad
Eficiencia.
Dimesilato de Lisdexanfetamina
Transtorno de déficit de atenção
Hiperatividade
Eficácia.
Lisdexamfetamine dimesylate
Attention deficit disorder
Hyperactivity
Efficiency.
topic Dimesilato de lisdexanfetamina
Desorden de déficit de atención
Hiperactividad
Eficiencia.
Dimesilato de Lisdexanfetamina
Transtorno de déficit de atenção
Hiperatividade
Eficácia.
Lisdexamfetamine dimesylate
Attention deficit disorder
Hyperactivity
Efficiency.
description Attention Deficit Hyperactivity Disorder (ADHD) is a neurological disorder that is associated with poor brain performance. Individuals with ADHD have dyslexia, a certain impulsiveness and difficulty concentrating, resulting in poor school development. Taking into account, about 2.5 million new cases are declared per year in Brazil, whether due to real necessity or mere mediocrity of the diagnosis. Lisdexamfetamine methylphenidate is the main representative of a new class of long-acting agents for the treatment of ADHD, in current scenarios it has been the drug traditionally used as first choice for the treatment of children and adolescents with ADHD. Therefore, the general objective of this study was to analyze the effects that lisdexamfetamine dimesylate has for individuals with ADHD. In the methodology, a literature review was carried out, including studies in Portuguese and published between 2017 and 2022. Data collection took place in PubMed, LILACS, Scielo and Google Scholar databases. In the results, the safety and efficacy of lisdexamfetamine dimesylate for patients with ADHD proved to be effective and positive. In the studies found, it was understood that this drug has as its mechanism of action the blockade of the reuptake of the neurotransmitter dopamine and the stimulus to its production and noradrenaline. This action is what makes the stimulant of this medicine effective.
publishDate 2023
dc.date.none.fl_str_mv 2023-02-13
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/40259
10.33448/rsd-v12i2.40259
url https://rsdjournal.org/index.php/rsd/article/view/40259
identifier_str_mv 10.33448/rsd-v12i2.40259
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/40259/32963
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 12 No. 2; e28412240259
Research, Society and Development; Vol. 12 Núm. 2; e28412240259
Research, Society and Development; v. 12 n. 2; e28412240259
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052618385653760